Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catlow

Showing results (341-350 of 363) with videos related to

Pageof 37
Sort By:
Journal of Medicinal Chemistry|January 20, 2018
Synthesis and Pharmacological Characterization of C4<sub>β</sub>-Amide-Substituted 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1 S,2 S,4 S,5 R,6 S)-2-Amino-4-[(3-methoxybenzoyl)amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2794193), a Highly Potent and Selective mGlu<sub>3</sub> Receptor AgonistJames A Monn, Steven S Henry, Steven M Massey, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 27, 2019
Modulation of TARP <i>γ</i>8-Containing AMPA Receptors as a Novel Therapeutic Approach for Chronic PainKelly L Knopp, Rosa Maria A Simmons, Wenhong Guo, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2013
Discovery of (1R,2R)-N-(4-(6-isopropylpyridin-2-yl)-3-(2-methyl-2H-indazol-5-yl)isothiazol-5-yl)-2-methylcyclopropanecarboxamide, a potent and orally efficacious mGlu5 receptor negative allosteric modulatorJunliang Hao, Veronique Dehlinger, Adam M Fivush, et al.
Pharmacology Research & Perspectives|January 19, 2017
Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptorsJeffrey M Witkin, Linda M Rorick-Kehn, Mark J Benvenga, et al.
Faraday Discussions|August 10, 2018
Application of new nanoparticle structures as catalysts: general discussionFrancesca Baletto, Maurits Boeije, Alexis Bordet, et al.
Nature Medicine|November 8, 2016
Forebrain-selective AMPA-receptor antagonism guided by TARP γ-8 as an antiepileptic mechanismAkihiko S Kato, Kevin D Burris, Kevin M Gardinier, et al.
Faraday Discussions|June 22, 2016
Bridging model and real catalysts: general discussionCharles Campbell, Michael Bowker, Michail Stamatakis, et al.
Faraday Discussions|May 19, 2021
Theory: general discussionMegha Anand, Francesca Baletto, Aram Bugaev, et al.
Faraday Discussions|April 22, 2017
Catalysis for Fuels: general discussionHans Niemantsverdriet, Pieter van Helden, Emiel Hensen, et al.
Journal of Medicinal Chemistry|August 28, 2015
Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor AgonistJames A Monn, Lourdes Prieto, Lorena Taboada, et al.
Pageof 37

Showing results (341-350 of 363) with videos related to

Sort By:
Pageof 37
Journal of Medicinal Chemistry|January 20, 2018
Synthesis and Pharmacological Characterization of C4<sub>β</sub>-Amide-Substituted 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1 S,2 S,4 S,5 R,6 S)-2-Amino-4-[(3-methoxybenzoyl)amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2794193), a Highly Potent and Selective mGlu<sub>3</sub> Receptor AgonistJames A Monn, Steven S Henry, Steven M Massey, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 27, 2019
Modulation of TARP <i>γ</i>8-Containing AMPA Receptors as a Novel Therapeutic Approach for Chronic PainKelly L Knopp, Rosa Maria A Simmons, Wenhong Guo, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2013
Discovery of (1R,2R)-N-(4-(6-isopropylpyridin-2-yl)-3-(2-methyl-2H-indazol-5-yl)isothiazol-5-yl)-2-methylcyclopropanecarboxamide, a potent and orally efficacious mGlu5 receptor negative allosteric modulatorJunliang Hao, Veronique Dehlinger, Adam M Fivush, et al.
Pharmacology Research & Perspectives|January 19, 2017
Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptorsJeffrey M Witkin, Linda M Rorick-Kehn, Mark J Benvenga, et al.
Faraday Discussions|August 10, 2018
Application of new nanoparticle structures as catalysts: general discussionFrancesca Baletto, Maurits Boeije, Alexis Bordet, et al.
Nature Medicine|November 8, 2016
Forebrain-selective AMPA-receptor antagonism guided by TARP γ-8 as an antiepileptic mechanismAkihiko S Kato, Kevin D Burris, Kevin M Gardinier, et al.
Faraday Discussions|June 22, 2016
Bridging model and real catalysts: general discussionCharles Campbell, Michael Bowker, Michail Stamatakis, et al.
Faraday Discussions|May 19, 2021
Theory: general discussionMegha Anand, Francesca Baletto, Aram Bugaev, et al.
Faraday Discussions|April 22, 2017
Catalysis for Fuels: general discussionHans Niemantsverdriet, Pieter van Helden, Emiel Hensen, et al.
Journal of Medicinal Chemistry|August 28, 2015
Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor AgonistJames A Monn, Lourdes Prieto, Lorena Taboada, et al.
Pageof 37